Show simple item record

dc.contributor.authorLee, Mei-Hsuanen_US
dc.contributor.authorHuang, Chung-Fengen_US
dc.contributor.authorLai, Hsueh-Chouen_US
dc.contributor.authorLin, Chun-Yenen_US
dc.contributor.authorDai, Chia-Yenen_US
dc.contributor.authorLiu, Chun-Jenen_US
dc.contributor.authorWang, Jing-Houngen_US
dc.contributor.authorHuang, Jee-Fuen_US
dc.contributor.authorSu, Wen-Pangen_US
dc.contributor.authorYang, Hung-Chihen_US
dc.contributor.authorKee, Kwong-Mingen_US
dc.contributor.authorYeh, Ming-Lunen_US
dc.contributor.authorChuang, Po-Hengen_US
dc.contributor.authorHsu, Shih-Jeren_US
dc.contributor.authorHuang, Ching-Ien_US
dc.contributor.authorKao, Jung-Taen_US
dc.contributor.authorChen, Chieh-Changen_US
dc.contributor.authorChen, Sheng-Hungen_US
dc.contributor.authorJeng, Wen-Jueien_US
dc.contributor.authorYang, Hwai-Ien_US
dc.contributor.authorYuan, Yongen_US
dc.contributor.authorLu, Sheng-Nanen_US
dc.contributor.authorSheen, I-Shyanen_US
dc.contributor.authorLiu, Chen-Huaen_US
dc.contributor.authorPeng, Cheng-Yuanen_US
dc.contributor.authorKao, Jia-Horngen_US
dc.contributor.authorYu, Ming-Lungen_US
dc.contributor.authorChuang, Wan-Longen_US
dc.contributor.authorChen, Chien-Jenen_US
dc.date.accessioned2017-07-24T18:33:20Z
dc.date.issued2017en_US
dc.identifier.citationLee, M., C. Huang, H. Lai, C. Lin, C. Dai, C. Liu, J. Wang, et al. 2017. “Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients.” Scientific Reports 7 (1): 3718. doi:10.1038/s41598-017-02313-y. http://dx.doi.org/10.1038/s41598-017-02313-y.en
dc.identifier.issnen
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:33490704
dc.description.abstractThis follow-up study enrolled chronic hepatitis C patients to evaluate the treatment efficacy and to identify post-treatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among patients with a sustained virological response (SVR) or nonsustained virological response (NSVR). A total of 4639 patients who received pegylated interferon and ribavirin during 2004–2013 were followed until December 2014. HCC was confirmed through health examinations and data linkage with a national database. A total of 233 HCC cases were reported after 26,163 person-years of follow-up, indicating an incidence of 8.9 per 1000 person-years: 6.9 for SVR and 21.6 for NSVR per 1000 person-years. The associated risk of HCC in patients with SVR was 0.37 (0.22–0.63) for those without cirrhosis and 0.54 (0.31–0.92) for those with cirrhosis compared with their respective counterparts with NSVR. Among patients with SVR, advanced age, male gender, cirrhosis, decreased platelet count, and increased aspartate aminotransferase and α-fetoprotein levels were associated with HCC (p < 0.001). The treatment of chronic hepatitis C patients before they developed cirrhosis showed a higher efficacy than did the treatment of those who had already developed cirrhosis. Patients with SVR may still have a risk of HCC and need to be regularly monitored.en
dc.language.isoen_USen
dc.publisherNature Publishing Group UKen
dc.relation.isversionofdoi:10.1038/s41598-017-02313-yen
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473811/pdf/en
dash.licenseLAAen_US
dc.titleClinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patientsen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalScientific Reportsen
dash.depositing.authorYu, Ming-Lungen_US
dc.date.available2017-07-24T18:33:20Z
dc.identifier.doi10.1038/s41598-017-02313-y*
dash.authorsorderedfalse
dash.contributor.affiliatedYu, Ming-Lung


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record